NasdaqGS - Nasdaq Real Time Price USD

Sarepta Therapeutics, Inc. (SRPT)

Time to buy SRPT?
37.60
-1.01
(-2.62%)
At close: May 30 at 4:00:00 PM EDT
37.50
-0.10
(-0.27%)
After hours: May 30 at 7:59:12 PM EDT
Time to buy SRPT?
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,233,371
1,901,979
1,243,336
933,013
701,887
Cost of Revenue
406,104
319,099
150,343
139,989
97,049
Gross Profit
1,827,267
1,582,880
1,092,993
793,024
604,838
Operating Expense
1,944,477
1,364,799
1,360,817
1,329,225
1,054,548
Operating Income
-117,210
218,081
-267,824
-536,201
-449,710
Net Non Operating Interest Income Expense
45,570
53,376
63,959
-25,525
-63,014
Other Income Expense
-92,552
-10,683
-316,233
-128,237
93,776
Pretax Income
-164,192
260,774
-520,098
-689,963
-418,948
Tax Provision
84,196
25,535
15,879
13,525
-168
Net Income Common Stockholders
-248,388
235,239
-535,977
-703,488
-418,780
Diluted NI Available to Com Stockholders
-248,817
235,239
-535,977
-703,488
-418,780
Basic EPS
-2.64
2.34
-5.80
-8.03
-5.15
Diluted EPS
-2.64
2.34
-5.80
-8.03
-5.15
Basic Average Shares
108,717.75
107,875
92,398
87,559
81,262
Diluted Average Shares
108,717.75
107,875
92,398
87,559
81,262
Total Operating Income as Reported
-117,210
218,081
-267,824
-536,201
-459,710
Total Expenses
2,350,581
1,683,898
1,511,160
1,469,214
1,151,597
Net Income from Continuing & Discontinued Operation
-248,388
235,239
-535,977
-703,488
-418,780
Normalized Income
-194,749.80
242,308.88
-205,085.50
-607,648.36
-411,492
Interest Income
64,298
71,767
85,969
27,723
511
Interest Expense
18,728
18,391
22,010
53,248
63,525
Net Interest Income
45,570
53,376
63,959
-25,525
-63,014
EBIT
-145,464
279,165
-498,088
-636,715
-355,423
EBITDA
-106,506
316,889
-453,691
-594,851
-317,406
Reconciled Cost of Revenue
369,551
283,780
107,505
98,839
59,738
Reconciled Depreciation
38,958
37,724
44,397
41,864
38,017
Net Income from Continuing Operation Net Minority Interest
-248,388
235,239
-535,977
-703,488
-418,780
Total Unusual Items Excluding Goodwill
-89,397
-7,838
-418,850
-121,316
-7,288
Total Unusual Items
-89,397
-7,838
-418,850
-121,316
-7,288
Normalized EBITDA
-17,109
324,727
-34,841
-473,535
-310,118
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-35,758.80
-768.12
-87,958.50
-25,476.36
0
12/31/2021 - 6/4/1997

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

RCKT Rocket Pharmaceuticals, Inc.
2.5100
-4.20%
 
SMMT Summit Therapeutics Inc.
18.22
-30.50%
 
NTLA Intellia Therapeutics, Inc.
6.87
-7.79%
 
ARWR Arrowhead Pharmaceuticals, Inc.
16.07
-4.46%
 
VKTX Viking Therapeutics, Inc.
26.80
-4.83%
 
REGN Regeneron Pharmaceuticals, Inc.
490.28
-19.01%
 
IOVA Iovance Biotherapeutics, Inc.
1.7500
-4.37%
 
ALNY Alnylam Pharmaceuticals, Inc.
304.56
+3.98%
 
BMRN BioMarin Pharmaceutical Inc.
58.07
-0.82%
 
ACAD ACADIA Pharmaceuticals Inc.
21.57
-3.23%